SLCO3A1 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
endothelial cell	23 studies	34% ± 12%	Explore
oligodendrocyte	16 studies	65% ± 20%	Explore
pericyte	14 studies	29% ± 13%	Explore
fibroblast	13 studies	30% ± 13%	Explore
glutamatergic neuron	11 studies	47% ± 21%	Explore
smooth muscle cell	11 studies	34% ± 12%	Explore
mast cell	10 studies	25% ± 7%	Explore
type I pneumocyte	9 studies	41% ± 16%	Explore
classical monocyte	9 studies	28% ± 14%	Explore
GABAergic neuron	9 studies	47% ± 25%	Explore
macrophage	9 studies	29% ± 9%	Explore
ciliated cell	8 studies	35% ± 18%	Explore
monocyte	8 studies	43% ± 17%	Explore
neuron	7 studies	37% ± 23%	Explore
myeloid cell	7 studies	29% ± 8%	Explore
dendritic cell	7 studies	32% ± 11%	Explore
natural killer cell	6 studies	25% ± 7%	Explore
astrocyte	6 studies	31% ± 15%	Explore
mesothelial cell	6 studies	46% ± 12%	Explore
type II pneumocyte	6 studies	39% ± 12%	Explore
basal cell	6 studies	41% ± 20%	Explore
non-classical monocyte	5 studies	39% ± 10%	Explore
CD4-positive, alpha-beta T cell	5 studies	22% ± 4%	Explore
epithelial cell	5 studies	44% ± 25%	Explore
cardiac muscle cell	5 studies	51% ± 10%	Explore
interneuron	5 studies	54% ± 29%	Explore
retinal ganglion cell	4 studies	30% ± 7%	Explore
T cell	4 studies	29% ± 8%	Explore
capillary endothelial cell	4 studies	26% ± 11%	Explore
club cell	4 studies	23% ± 4%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	3 studies	26% ± 5%	Explore
cholangiocyte	3 studies	35% ± 12%	Explore
hepatic stellate cell	3 studies	32% ± 16%	Explore
CD16-negative, CD56-bright natural killer cell, human	3 studies	20% ± 2%	Explore
CD16-positive, CD56-dim natural killer cell, human	3 studies	20% ± 3%	Explore
GABAergic interneuron	3 studies	39% ± 11%	Explore
microglial cell	3 studies	22% ± 5%	Explore
effector memory CD8-positive, alpha-beta T cell	3 studies	23% ± 2%	Explore
endothelial cell of artery	3 studies	21% ± 4%	Explore
vein endothelial cell	3 studies	27% ± 3%	Explore
ON-bipolar cell	3 studies	23% ± 5%	Explore
endothelial cell of lymphatic vessel	3 studies	20% ± 3%	Explore
endothelial cell of vascular tree	3 studies	26% ± 6%	Explore
CD8-positive, alpha-beta T cell	3 studies	21% ± 4%	Explore
adventitial cell	3 studies	27% ± 14%	Explore
alveolar macrophage	3 studies	37% ± 10%	Explore
lymphocyte	3 studies	33% ± 9%	Explore
granule cell	3 studies	42% ± 19%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
brain	16 studies	43% ± 19%	Explore
lung	6 studies	30% ± 9%	Explore
heart	4 studies	35% ± 7%	Explore
peripheral blood	3 studies	27% ± 2%	Explore
adipose	3 studies	24% ± 5%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
esophagus	100%	1755.81	1444 / 1445	96%	20.65	175 / 183
thymus	100%	2757.73	653 / 653	95%	13.83	576 / 605
ovary	95%	986.19	171 / 180	99%	23.44	424 / 430
lung	100%	3212.81	578 / 578	93%	16.93	1078 / 1155
adrenal gland	100%	1237.99	258 / 258	93%	11.37	214 / 230
brain	99%	1880.91	2605 / 2642	92%	9.48	646 / 705
uterus	100%	1374.75	170 / 170	88%	13.39	405 / 459
kidney	97%	1348.26	86 / 89	92%	11.83	825 / 901
breast	100%	2087.88	458 / 459	77%	7.19	866 / 1118
bladder	95%	1339.90	20 / 21	77%	8.34	387 / 504
intestine	92%	836.55	885 / 966	80%	7.68	422 / 527
stomach	77%	759.33	277 / 359	92%	9.86	263 / 286
skin	100%	2627.31	1800 / 1809	63%	5.73	296 / 472
pancreas	40%	267.10	132 / 328	94%	11.53	168 / 178
prostate	96%	1088.04	236 / 245	38%	1.85	190 / 502
adipose	100%	2721.72	1204 / 1204	0%	0	0 / 0
spleen	100%	2745.44	241 / 241	0%	0	0 / 0
blood vessel	100%	2086.98	1331 / 1335	0%	0	0 / 0
heart	99%	2727.71	855 / 861	0%	0	0 / 0
tonsil	0%	0	0 / 0	98%	13.69	44 / 45
lymph node	0%	0	0 / 0	83%	5.98	24 / 29
peripheral blood	81%	3597.57	751 / 929	0%	0	0 / 0
muscle	72%	507.03	580 / 803	0%	0	0 / 0
liver	27%	168.86	61 / 226	41%	3.97	167 / 406
eye	0%	0	0 / 0	11%	0.47	9 / 80
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0051092	Biological process	positive regulation of NF-kappaB transcription factor activity
GO_0006811	Biological process	monoatomic ion transport
GO_0043252	Biological process	sodium-independent organic anion transport
GO_0015732	Biological process	prostaglandin transport
GO_0001934	Biological process	positive regulation of protein phosphorylation
GO_0055085	Biological process	transmembrane transport
GO_0150104	Biological process	transport across blood-brain barrier
GO_0016324	Cellular component	apical plasma membrane
GO_0005886	Cellular component	plasma membrane
GO_0009925	Cellular component	basal plasma membrane
GO_0016323	Cellular component	basolateral plasma membrane
GO_0015132	Molecular function	prostaglandin transmembrane transporter activity
GO_0008514	Molecular function	organic anion transmembrane transporter activity
GO_0015347	Molecular function	sodium-independent organic anion transmembrane transporter activity

IV. Literature review

[source]

Gene name	SLCO3A1
Protein name	Solute carrier organic anion transporter family member 3A1 (OATP3A1) (Organic anion transporter polypeptide-related protein 3) (OATP-RP3) (OATPRP3) (Organic anion-transporting polypeptide D) (OATP-D) (PGE1 transporter) (Sodium-independent organic anion transporter D) (Solute carrier family 21 member 11) Solute carrier organic anion transporter family member 3A1
Synonyms	SLC21A11 OATP3A1 OATPD
Description	FUNCTION: Putative organic anion antiporter with apparent broad substrate specificity. Recognizes various substrates including thyroid hormone L-thyroxine, prostanoids such as prostaglandin E1 and E2, bile acids such as taurocholate, glycolate and glycochenodeoxycholate and peptide hormones such as L-arginine vasopressin, likely operating in a tissue-specific manner . The transport mechanism, its electrogenicity and potential tissue-specific counterions remain to be elucidated (Probable). .
Accessions	G3V3K4 ENST00000318445.11 [Q9UIG8-1] G3V2B7 ENST00000555210.1 Q9UIG8 ENST00000424469.2 [Q9UIG8-2] ENST00000555892.5 H0YJM0 ENST00000553304.1

SLCO3A1 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review